Streetbeat News

Price Targets

LEVI

Wells Fargo analyst Ike Boruchow has maintained an Equal-Weight rating on Levi Strauss (NYSE:LEVI) but reduced the price target from $18 to $17.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:50 pm

V

Wedbush analyst Moshe Katri has maintained an Outperform rating on Visa (NYSE:V) and increased the price target from $270 to $280.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:50 pm

AMTB

Keefe, Bruyette & Woods analyst Brady Gailey has maintained a 'Market Perform' rating on Amerant Bancorp (NYSE:AMTB) and increased the price target from $27 to $28, as reported on January 25, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:49 pm

AJG

Keefe, Bruyette & Woods analyst Meyer Shields has maintained an Underperform rating on Arthur J. Gallagher (NYSE:AJG) and reduced the price target from $249 to $246.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:47 pm

VLY

Wedbush analyst David Chiaverini has maintained a Neutral rating on Valley National Bancorp (NASDAQ:VLY) but has lowered the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:42 pm

BANC

Wedbush analyst David Chiaverini has maintained a Neutral rating on Banc of California (NYSE:BANC) and increased the price target from $14 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:41 pm

DNTH

Wedbush analyst Laura Chico has maintained an Outperform rating on Dianthus Therapeutics (NASDAQ:DNTH) and increased the price target from $23 to $24.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:38 pm

AVTR

Avantor's stock (AVTR) is trading higher following an Outperform rating reaffirmation and a price target increase from $22.5 to $26 by Raymond James.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:38 pm

VERA

Wedbush analyst Laura Chico has maintained a Neutral rating on Vera Therapeutics (NASDAQ:VERA) and increased the price target from $16 to $21.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:37 pm

FUSN

Wedbush analyst David Nierengarten has reiterated an Outperform rating on Fusion Pharmaceuticals (NASDAQ:FUSN) and maintained a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:35 pm